Lotte Biologics is conducting a rights offering worth KRW 255.3 billion to raise funds for the construction of its Songdo Bio Campus Plant 1.


Aerial view of Lotte Biologics Songdo Bio Campus Plant 1 in Yeonsu-gu, Incheon. Lotte Biologics

Aerial view of Lotte Biologics Songdo Bio Campus Plant 1 in Yeonsu-gu, Incheon. Lotte Biologics

View original image

According to industry sources on July 7, Lotte Biologics held a board meeting the previous day and decided on a paid-in capital increase amounting to KRW 255,395,220,000. All of the funds raised will be used as facility capital for Songdo Bio Campus Plant 1.


The new shares to be issued through this capital increase will total 4,209,000 common shares. The issue price for the new shares has been set at KRW 60,658 per share. The record date for the allocation of new shares is set for July 20, and subscription and payment by existing shareholders will take place on August 19. Any forfeited shares or fractional shares resulting from the subscription process will not be issued.



The final decision on whether existing shareholders, such as Lotte Corporation, Lotte Holdings, and Hotel Lotte, will participate in the rights offering will be made later by each company's board of directors. Previously, Lotte Corporation provided a total of KRW 728.1 billion in support to Lotte Biologics through March of this year, and upon completion of this capital increase, the cumulative investment in Lotte Group's bio business is expected to reach KRW 1 trillion.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing